Reaction

Metastases To Skin reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,011 reports · 45 co-occurring drugs

As of the last recalculation, Metastases To Skin appears in 1,011 FAERS reports alongside 45 co-occurring drug terms. The strongest observed disproportionality signal is EXEMESTANE (PRR 135.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Exemestane	124	135.7	136.5
Ado-Trastuzumab Emtansine	48	123.0	123.7
Fulvestrant	160	118.3	118.9
Everolimus Tablets	74	98.0	98.4
Lapatinib	59	83.1	83.4
Goserelin	49	78.9	79.2
Letrozole Tablets	133	65.4	65.6
Letrozole	161	63.8	64.0
Everolimus	134	62.3	62.5
Trastuzumab	168	60.2	60.4
Ribociclib	70	49.0	49.1
Capecitabine	175	47.4	47.5
Pertuzumab	58	46.5	46.6
Docetaxel Anhydrous	111	38.0	38.0
Docetaxel	111	38.0	38.0
Fam-Trastuzumab Deruxtecan-Nxki	18	37.4	37.5
Dabrafenib	34	34.3	34.4
Paclitaxel	129	30.6	30.6
Paclitaxel (Aibumin-Bound)	100	27.7	27.7
Trametinib	30	26.3	26.3
Anastrozole Tablets	26	25.6	25.6
Zoledronic Acid	44	23.5	23.6
Gemcitabine Hydrochloride	57	23.4	23.4
Gemcitabine	42	22.9	22.9
Anastrozole	34	19.7	19.7
Cisplatin	63	17.6	17.7
Ursosiol	16	17.2	17.2
Doxorubicin	69	17.0	17.0
Ursodiol	16	15.4	15.4
Palbociclib	66	15.2	15.2
Fluorouracil Cream, 0.5%	53	15.0	15.1
Fluorouracil	53	14.8	14.8
Carboplatin	76	13.2	13.2
Durvalumab	12	12.3	12.3
Ipilimumab	25	12.2	12.2
Doxorubicin Hydrochloride	17	10.9	10.9
Sorafenib	10	10.0	10.0
Bevacizumab	56	9.8	9.8
Trifluridine And Tipiracil	5	9.6	9.6
Alpelisib	4	9.5	9.5
Nivolumab	42	9.3	9.3
Olaparib	9	8.9	8.9
Denosumab	72	7.8	7.8
Pazopanib Hydrochloride	10	7.7	7.7
Vemurafenib	4	6.9	6.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.